CANY
EOLS icon

Caxton Associates (New York)’s Evolus EOLS Stock Holding History

Caxton Associates (New York)’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,719
Closed -$136K – 524
2022
Q2 		$136K Hold
11,719
– – 0.01% 494
2022
Q1 		$131K Buy
+11,719
New +$99.9K 0.01% 470

Other funds holding EOLS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caxton Associates (New York)'s EOLS Position: Q3 2022 in Review

Caxton Associates (New York) sold out of Evolus (EOLS) in Q3 2022, closing a stake of 11,719 shares — an estimated $136K sold.

Caxton Associates (New York) first reported a position in EOLS in Q1 2022 and held it in 2 quarters. The position peaked at $136K in Q2 2022. 130 funds tracked by Wall St. Rank hold EOLS as of Q3 2022.

  • Caxton Associates (New York) reported no remaining Evolus position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,719 Evolus shares in Q3 2022, an estimated $136K.
  • Caxton Associates (New York) first reported a position in Evolus in Q1 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Evolus position peaked at $136K in Q2 2022.
  • 130 funds tracked by Wall St. Rank held Evolus as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.